Investor Relations

XBiotech is a clinical-stage biopharmaceutical company engaged in discovering and developing “True Human™” monoclonal antibodies for treating a variety of diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal immunization or otherwise engineered. It is believed that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. While focused on bringing its lead oncology product candidate (Xilonix™) to market, XBiotech is also developing a pipeline of other “True Human™” antibodies and a manufacturing system to reduce the cost of drug development.